Eric Joseph
Stock Analyst at JP Morgan
(1.33)
# 3,416
Out of 4,876 analysts
134
Total ratings
36.05%
Success rate
-11.38%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $44.12 | +45.06% | 3 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $2.42 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $2.53 | +1,639.13% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $6.37 | +9.89% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $49.84 | +34.43% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.32 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.25 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $11.64 | +157.73% | 7 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Upgrades: Neutral | n/a | $1.08 | - | 8 | Jan 13, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $5.17 | +170.79% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $36.91 | +92.36% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $36.72 | +17.10% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $10.51 | +261.56% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.52 | +1,413.16% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $6.67 | +154.87% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $3.30 | +536.36% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $16.80 | +185.71% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $7.50 | +33.33% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.97 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.81 | +728.73% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $1.40 | +328.57% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $5.03 | +98.81% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $4.60 | +139.13% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $56.19 | -27.03% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $8.94 | +1,018.57% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.52 | +863.95% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.44 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $3.83 | +187.21% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.02 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $4.33 | +2,671.36% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $7.21 | +4,060.89% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.20 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $11.30 | +342.48% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $2.31 | +289.61% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.65 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.35 | +1,687.23% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $0.73 | +1,678.63% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.54 | +1,933.65% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $44.12
Upside: +45.06%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.42
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $2.53
Upside: +1,639.13%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $6.37
Upside: +9.89%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $49.84
Upside: +34.43%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.32
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.25
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $11.64
Upside: +157.73%
IGM Biosciences
Jan 13, 2025
Upgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.17
Upside: +170.79%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $36.91
Upside: +92.36%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $36.72
Upside: +17.10%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $10.51
Upside: +261.56%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $1.52
Upside: +1,413.16%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $6.67
Upside: +154.87%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $3.30
Upside: +536.36%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $16.80
Upside: +185.71%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $7.50
Upside: +33.33%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.97
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.81
Upside: +728.73%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $1.40
Upside: +328.57%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $5.03
Upside: +98.81%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $4.60
Upside: +139.13%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $56.19
Upside: -27.03%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $8.94
Upside: +1,018.57%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.52
Upside: +863.95%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.44
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $3.83
Upside: +187.21%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $9.02
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $4.33
Upside: +2,671.36%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $7.21
Upside: +4,060.89%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.20
Upside: -
Jul 12, 2021
Initiates: Neutral
Price Target: $50
Current: $11.30
Upside: +342.48%
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $2.31
Upside: +289.61%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.65
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.35
Upside: +1,687.23%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $0.73
Upside: +1,678.63%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.54
Upside: +1,933.65%